FDA approves new drug for most common form of cystic fibrosis
(HealthDay)—A new drug to treat most cystic fibrosis patients has been approved by the U.S. Food and Drug Administration. Trikafta […]
(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. […] DURHAM, N.C.–(BUSINESS WIRE)–Mar. 12, 2019– Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the […] NEW YORK, December 21, 2018 (GLOBE NEWSWIRE) – Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and […] RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that the U.S. Food […] THURSDAY, Nov. 8, 2018 — A new version of an over-the-counter asthma inhaler that was taken off the market in […] FRIDAY, Oct. 12, 2018 — The U.S. Food and Drug Administration has approved the ID CORE XT DNA-based test to […] South San Francisco, CA — October 4, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: […] EWING, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ:ATRS) today announced the approval of Xyosted (testosterone enanthate) […] September 27, 2018 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Vizimpro […]approves
FDA approves venetoclax for chronic, small lymphocytic leukemia
FDA Approves Rocklatan
FDA Approves Elzonris (tagraxofusp-erzs), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma
FDA Approves New Version of OTC Primatene Mist
FDA Approves New DNA-Based Test to Verify Blood Compatibility
FDA Approves Genentech’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
FDA Approves Xyosted
FDA Approves Vizimpro